PT  - JOURNAL ARTICLE
AU  - MISHIMA, HIDEYUKI
AU  - IKENAGA, MASAKAZU
AU  - ISHIDA, HIDEYUKI
AU  - IWAMOTO, SHIGENORI
AU  - MORIMOTO, TAKASHI
AU  - NARAHARA, HIROYUKI
AU  - KATO, TAKESHI
AU  - TSUJIE, MASAKI
AU  - KITAI, TOSHIYUKI
AU  - FUKUNAGA, MUTSUMI
AU  - NAKANISHI, MASAYOSHI
AU  - TSUJINAKA, TOSHIMASA
AU  - FURUKAWA, HIROSHI
AU  - TAGUCHI, TETSUO
AU - OSAKA GASTROINTESTINAL CANCER CHEMOTHERAPY STUDY GROUP
TI  - Multicenter Phase II Study of Irinotecan Plus Bolus Fluorouracil/<em>l</em>-Leucovorin for Metastasic Colorectal Cancer
DP  - 2007 Mar 01
TA  - Anticancer Research
PG  - 1003--1008
VI  - 27
IP  - 2
4099  - http://ar.iiarjournals.org/content/27/2/1003.short
4100  - http://ar.iiarjournals.org/content/27/2/1003.full
SO  - Anticancer Res2007 Mar 01; 27
AB  - Treatment of metastatic colorectal cancer remains inadequate. Patients and Methods: In a multicentre Phase II study, irinotecan (100 mg/m2), 5-fluorouracil (5-FU) (500 mg/m2), and l-leucovorin (l-LV) (250 mg/m2) were administered on days 1, 8, and 15 of a five-week cycle. Forty-five patients were enrolled. Results: The objective response rate was 26.7%. The median survival time was 21.8 months and the one-year survival rate was 73.3%. The median number of cycles was 4.0, with a median relative dose intensity of 83.3% for both irinotecan and 5-FU. Grade 3 or 4 haematological toxicities were anaemia in four patients, leukopaenia in six patients, and neutropaenia in 15 patients, while non-haematological toxicities were diarrhoea in three patients, and nausea, vomiting, anorexia and increased transaminases in two patients each. No treatment-related deaths occurred. Conclusion: Irinotecan plus 5-FU/l-LV can be used to treat metastatic colorectal cancer on an outpatient basis. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved